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Background: Vaccination against influenza is recommended in patients with end-stage renal disease (ESRD).
However, so far, no systematic review has summarized the available evidence on the effectiveness and safety of
influenza vaccination in this patient group.
Methods: We conducted a systematic review and meta-analysis and assessed the quality of evidence using the
GRADE methodology. We searched MEDLINE, EMBASE, Cochrane Library databases, ClinicalTrials.gov, and reference
lists for studies on efficacy, effectiveness, and/or safety of seasonal influenza vaccination in patients with ESRD receiving
dialysis. All reported clinical outcomes were considered, including all-cause mortality, cardiac death, infectious death,
all-cause hospitalization, hospitalization due to influenza or pneumonia, hospitalization due to bacteremia, viremia, or
septicemia, hospitalization due to respiratory infection, ICU admission, and influenza-like illness.
Results: Five observational studies and no randomized-controlled trial were identified. In four studies, risk of bias was
high regarding all reported outcomes. Strong residual confounding was likely to be present in one study reporting on
three outcomes, as indicated by significant protective effects of vaccination outside influenza seasons. Therefore, the
statistically significant protective effects on all-cause mortality (vaccine effectiveness (VE), 32%; 95% CI, 24–39%), cardiac
death (VE, 16%; 95% CI, 1–29%), hospitalization due to influenza or pneumonia (VE, 14%; 95% CI, 7–20%), ICU admission
(VE, 81%; 95% CI, 63–86%), and influenza-like illness (VE, 12%; 95% CI, 10–14%) have to be taken with caution. According
to GRADE, the quality of the body of evidence was considered very low for all outcomes. No study reported on
laboratory-confirmed influenza virus infections or on safety endpoints.
Conclusions: Evidence on the protective effects of influenza vaccination in patients with ESRD is limited and of
very low quality. Since VE estimates in the available literature are prone to unmeasured confounding, studies using
randomization or quasi-experimental designs are needed to determine the extent by which vaccination prevents
influenza and related clinical outcomes in this at-risk population. However, given the high rates of health-endangering
events in these patients, even a low VE can be considered as sufficient to recommend annual influenza vaccination.
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Worldwide, about 1.9 million patients undergo renal
replacement therapy (hemodialysis, peritoneal dialysis,
kidney transplantation) due to end-stage renal disease
(ESRD) [1]. Although rates of incident ESRD have
decreased in some countries, the burden of ESRD is
increasing globally [2], mainly driven by an increase in
the prevalence of major risk factors such as diabetes
and hypertension [3]. Due to multifactorial causes,
patients with ESRD have an impaired innate and adap-
tive immune system, including defects in complement
activation and B- and T-cell function [4-6]. This func-
tional abnormality contributes to higher incidences and
severe courses of infectious diseases [7,8]. For example,
pulmonary infection-related mortality is up to 10-fold
higher in ESRD patients compared with the general
population [9]. To reduce influenza disease burden among
these patients, the World Health Organization and
many national immunization technical advisory groups
recommend annual vaccination against seasonal influ-
enza [10-13].
Although studies suggest that immunogenicity might
be reduced among ESRD patients [14], antibody levels
regarded as protective have been found in 53 to 90% of
dialysis patients [15,16]. However, it is unclear to which
degree these antibody levels finally translate into the
prevention of clinical outcomes. A recent methodological
study indicated that no systematic review has been
published thus far on the efficacy, effectiveness, and
safety of seasonal influenza vaccination in patients with
ESRD receiving dialysis [17]. We therefore performed a
respective systematic review and meta-analysis and used
the methodology suggested by the Grading of Recom-
mendations Assessment, Development and Evaluation
(GRADE) working group to rate the quality of the body
of evidence for each outcome.
Methods
Search strategy and selection criteria
This systematic review was performed according to the
Preferred Reporting Items for Systematic Reviews and
Meta-analysis (PRISMA) statement [18]. The literature
search was performed irrespective of study design (ex-
perimental and observational) and publication language.
The electronic databases searched were MEDLINE,
EMBASE, Cochrane Central Register of Controlled
Trials, Cochrane Database of Systematic Reviews, and
Database of Abstracts of Reviews of Effects (date of last
search: 07 May 2014). The complete search strategy is
shown in Additional file 1. In addition, we searched for
unpublished or ongoing studies in ClinicalTrials.gov.
Electronic searches were complemented by manually
searching all reference lists of identified studies and
reviews for additional studies.Studies had to meet the following a priori defined
inclusion criteria: i) original report on efficacy, effective-
ness, and/or safety of vaccines against seasonal influenza
in patients with ESRD receiving either hemodialysis or
peritoneal dialysis, and ii) control participants had to
be either unvaccinated or must have received placebo.
We excluded studies in which participants in the inter-
vention arm had received more than one influenza dose
in a given season.
Data extraction and risk of bias assessment
Two reviewers (CR and TH) independently screened titles
and abstracts to identify potentially eligible studies which
were then reviewed as full text. Disagreements were
resolved by discussions until consensus was achieved.
From eligible studies, two independent investigators (CR
and TH) extracted study characteristics and assessed risk
of bias, using standardized forms. Disagreements between
extractors were resolved by discussion. From each study,
the following information was extracted: study design,
country, study period, data source(s), population size,
inclusion and exclusion criteria for participants, age at
vaccination, sex, mean duration on dialysis, ethnicity,
duration of follow-up, reported comorbidities, source
of information on vaccination, vaccine used, circulating
influenza strains, match/mismatch between vaccine and
circulating strain, relative risk (RR), odds ratio (OR) or
hazard ratio (HR) for defined outcomes, risk difference
(RD), confounder-adjusted estimates, confounders con-
sidered, and control period (off-season) estimates. We
used the tool developed by the Critical Appraisal Skills
Programme [19] to assess risk of bias in the included
studies. According to the suggestions by the Cochrane
Collaboration [20], we made this assessment separately
for each outcome and expressed the result as a consid-
ered judgment, using the categories “high risk of bias”,
“low risk of bias”, and “unclear risk of bias”.
Assessment of the quality of a body of evidence
For each outcome, the quality of the respective body of
evidence (i.e., across all included studies) was assessed
using the GRADE methodology [21,22]. According to
GRADE, evidence on the effects of an intervention is
categorized into four levels of quality: very low, low,
moderate, and high. Bodies of evidence from randomized
controlled trials (RCTs) start as high quality evidence,
whereas those from studies with other designs (obser-
vational studies) start as low quality evidence. According
to a set of predefined criteria, evidence quality can
be increased or decreased. Further details on GRADE
can be found elsewhere [21,22]. In order to assess the
best available evidence, we used the results of the
confounder-adjusted analyses to determine GRADE
evidence quality.
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RRs, ORs, HRs, and RDs and corresponding 95% con-
fidence intervals (95% CIs) were either calculated or
extracted directly from the publications. Vaccine effect-
iveness (VE) was calculated as 1 – RR × 100. To express
the number of individuals needed to be vaccinated to
prevent one case of a particular outcome, we calculated
the number needed to vaccinate (NNV) as 1/RD.
Where data from more than one study for a given out-
come were available, we performed a meta-analysis, using
a random-effects model to account for heterogeneity. If a
single study reported data from more than one season,
these point estimates were pooled prior to meta-analysis.
I2 was used to quantify the extent of heterogeneity.
Confounder-adjusted in-season estimates were pooled
if they were adjusted at least for age, sex, and comor-
bidities. Since two studies covered patients that might
be different compared to the patients on continuous
hemodialysis included in the remaining studies, namely
patients with newly diagnosed ESRD [23] or patients on
peritoneal dialysis [24], we conducted a sensitivity ana-
lysis by stepwise excluding data from i) patients on
peritoneal dialysis and ii) with newly diagnosed ESRD
from the meta-analysis on all-cause mortality and
hospitalization due to influenza or pneumonia.
We evaluated the presence of residual confounding by
contrasting estimates of VE measured during the influ-
enza season to VE estimates measured during “controlFigure 1 Flow chart for the systematic literature search and study selec
patients with end-stage renal disease.periods” outside the influenza season in the same studies
(so-called “pseudo-effectiveness”). This approach makes
the assumption that vaccination is effective against
influenza-related outcomes only during the influenza
season when influenza virus is circulating. Consequently,
all differences in outcomes between vaccinated and non-
vaccinated participants measured outside the influenza
season cannot be attributed to vaccination, but must be
due to other factors which differ between groups. The
aim of adjustment for confounders in statistical analyses
is to eliminate the influence of such factors. Residual
confounding was therefore defined as present if the
confounder-adjusted estimate showed a statistically sig-
nificant effect of vaccination on a given outcome in the
absence of virus circulation, i.e., during a control period.
Formal testing for publication bias was not performed
because of the small number of identified studies. Calcu-
lations were done using STATA 12 (StataCorp, College
Station, TX, USA) and RevMan 5.2 (Cochrane Collabor-
ation). GRADE evidence profiles were created using the
GRADEpro software (GRADE working group).Results
Selection of studies and study characteristics
We identified, in the initial search, 1,541 records in elec-
tronic databases (Figure 1) and finally included a total of
five studies in this review after applying the inclusion andtion related to influenza vaccine efficacy/effectiveness outcomes in
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reported in Additional file 2.
All included studies were retrospective cohort studies
[23-27]. No RCTs, experimental, or quasi-experimental
studies were identified. Four studies were conducted in
the US and one in Taiwan; Table 1 presents the baseline
characteristics of the studies. All four studies from the
US identified patients with ESRD through dialysis facility
networks (US Renal Data System, USRDS) during different
influenza seasons [24-27]. The study from Taiwan used
data from a National Health Insurance program. Three
studies included patients on hemodialysis only [23,26,27],
and the other two studies [24,25] comprised patients
on hemodialysis and patients on peritoneal dialysis. In
all studies, the main cause of ESRD was underlying
diabetes mellitus. Two studies provided data on the
proportion of patients with previous kidney transplant-
ation [23,27] and one study censored patients at the
time of transplantation [26].
Two US studies reported data of the same influenza
season [24,26]. To avoid analyzing data from overlapping
populations, we decided to analyze data from hemodialysis
patients from the more recent publication [26] and those
from patients on peritoneal dialysis from the older publi-
cation [24].
Reported outcomes
Overall, nine different clinical outcomes were reported
(Table 2). All-cause mortality, all-cause hospitalization,
and hospitalization due to influenza or pneumonia were
addressed by at least two studies, whereas the remaining
outcomes were reported by one study each.
For the assessment of risk of bias, two studies measured
“pseudo-effectiveness” of influenza-related outcomes out-
side influenza seasons [25,26]. From the article of Bond
et al. [25] we extracted off-season estimates calculated for
the months June to August; from the article McGrath
et al. [26] we used off-season estimates that were calcu-
lated for the pre-influenza period, when, according to the
national influenza surveillance data, less than 10% of
isolates were positive for influenza. In addition, one study
compared vaccinated patients in vaccine-well-matched
years with those in mismatched years [26]. The latter
study exploits the year-to-year variation of match of the
vaccine virus to the circulating wild virus strain and
assumes that vaccination was effective only during seasons
with a good match, whereas it had only minimal effect
during mismatched seasons. In season 1997/1998, which
was covered by this study, circulating A(H3N2) influenza
strains did not match the vaccine strain [28,29].
Risk of bias assessment in individual studies
Risk of bias assessment of the included studies is shown in
Table 3. In four studies, risk of bias was high regarding allreported outcomes [23,24,26,27], and was mainly influ-
enced by missing baseline data of the vaccinated vs. unvac-
cinated cohort [24,27] and insufficient controlling for
confounders, as, for example, indicated by significant VE
estimates during “control periods” or during “mismatched”
seasons (see above) [26]. In one study, risk of bias was
unclear [25] owing to self-reported vaccination status.
Vaccine effectiveness and vaccine safety
Crude and adjusted ORs for all reported outcomes are
shown in Table 3. Forest plots are shown in Figure 2 and
variables that were used in the final multivariate model
are reported in Additional file 3. Regarding mortality,
statistically significant estimates indicating a protective
effect of vaccination were found for all-cause mortality
(pooled confounder-adjusted VE, 32%; 95% CI, 24–39%;
I2 = 83%; NNV: 15) and cardiac death (adjusted VE, 16%;
95% CI, 2–29%; NNV: 125), but not for death due to
infection (adjusted VE, 17%; 95% CI, −5%–35%) (for def-
inition of outcomes, see footnotes in Table 3). However,
one of two studies [26] showed a significant protective
effect of vaccination for all-cause mortality also in the
absence of influenza virus circulation (VE, 55%; 95% CI,
50–59%), indicating residual confounding. The other
study that provided a point estimate during the off-season
showed no statistically significant effects [25].
Regarding hospitalization, significant protective effects
of influenza vaccination were observed for the outcomes
hospitalization due to influenza or pneumonia (pooled
adjusted VE, 14%; 95% CI, 7–20%; I2 = 58%; NNV: 42) and
ICU admission (adjusted VE, 81%; 95% CI, 63–86%; NNV:
18). No significant effects were found for all-cause
hospitalization (pooled adjusted VE, 12%; 95% CI, −6–26%;
I2 = 70%), hospitalization due to bacteremia, viremia, or
septicemia (adjusted VE, 27%; 95% CI, −32–68%) and
hospitalization due to respiratory infection (adjusted VE,
13%; 95% CI, −9–31%). A significant off-season estimate
indicated the presence of residual confounding for the
effect on hospitalization due to influenza or pneumonia
(adjusted off-season VE, 26%; 95% CI, 15–36%). Likewise,
effect on influenza-like illness was likely to be prone to
residual confounding, indicated by a significant off-season
VE which was even higher than the in-season VE (Table 3).
The sensitivity analysis revealed that the removal of data
of patients on peritoneal dialysis [24] or of those with
newly diagnosed ESRD [23] did not affect point estimates
significantly (Additional file 4).
Laboratory-confirmed influenza infections were not
reported. None of the studies provided data on vaccine
safety, neither on local nor on systemic adverse events.
Quality of evidence
The body of evidence on influenza VE regarding all
reported outcomes was rated as being of very low quality
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patients (%)
















vacc.: 60.6 ± 15.2 vacc.: 50.8 vacc.: 4.5 ± 3 .6 vacc.: 92.6 USRDS; ICD-9-CM codes Not reported vacc.: n = 14,226
unvacc.: 57.9 ± 15.9 unvacc.: 52.5 unvacc.: 4.8 ± 4.1 unvacc.: 90.4 unvacc.: n = 5,994
Gilbertson





vacc.: 40.3 Proportion > 4 yrs
on dialysis:
01 USRDS; ICD-9-CM codes1 Not reported Patients on peritoneal
dialysis: n = 13,091
unvacc.: 40–64:
64.7%; 65+: 46.2%






vacc.: 62.3–63.92 vacc.: 52.2-53.02 Proportion > 4 yrs
on dialysis:
100 USRDS; ICD-9-CM codes H3N2 (all seasons) vacc.: n = 52,287–61,8002






all: 60.3 all: 51.1 Proportion < 5 yrs
on dialysis:






vacc.: 70.2 ± 9.96 vacc.: 50.3 Patients with “newly
diagnosed” ESRD
100 Universal insurance data,
National Health Insurance
program
Not reported vacc.: n = 831
unvacc.: n = 3,187
unvacc.: 59.4 ± 14.5 unvacc.: 48.7
Total study population Total: n = 174,6633
ESRD, end-stage renal disease; vacc., vaccinated; unvacc., non-vaccinated.
1Since Gilbertson et al. and McGrath et al. used the same database, but McGrath included patients on hemodialysis only, patients on peritoneal dialysis were extracted from the study of Gilbertson et al.
2Range over 4 seasons.
































Bond et al. [25] + – – – – – + –
Gilbertson et al. [24] +1 + + +2 – – – –
McGrath et al. [26] + – + – + – + –
Slinin et al. [27] – – + – – – – –
Wang et al. [23] + + + +3 – + – –
1Additional outcomes reported: cardiac death, death through infection.
2Additional outcomes reported: hospitalization due to bacteremia/viremia/septicemia; hospitalization due to respiratory infection.
3Additional outcomes reported: hospitalization due to bacteremia/viremia/septicemia; hospitalization due to heart disease; hospitalization due to respiratory failure.
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evidence profile). Since data on vaccine safety could not
be extracted, no rating of evidence quality could be
performed.
Discussion
Our results indicate that there is only very low quality
evidence that influenza vaccination of patients with ESRD
can prevent mortality, hospitalization, or other clinical
outcomes. Although pooled estimates showed small to
moderate protective effects against all-cause mortality
and hospitalization due to influenza or pneumonia in
this patient sub-group, VE that was measured outside
influenza seasons showed even greater protective effects,
thereby strongly indicating residual confounding. Protect-
ive effects against other clinical outcomes were either not
statistically significant or only reported by single studies
with a high risk of bias.
There are a few immunogenicity studies published that
suggested that ESRD patients might have an impaired
immune-response to inactivated influenza vaccines [14].
However, other studies showed contradicting results and
it remains unclear how well seroprotection rates translate
into protection against clinical outcomes in general and
how well humoral response is sufficient for protection in
this patient sub-group in particular [15,16]. Recently, the
European Medicines Agency has changed its policy in the
approval of seasonal influenza vaccines and has withdrawn
the “Note for Guidance on Harmonisation of Require-
ments for Influenza Vaccines (CPMP/BWP/214/96)” [30].
According to the European Medicines Agency, post-
marketing studies monitoring the clinical benefit and
risk profile of seasonal influenza vaccines should be
strengthened, whereas providing immunogenicity data
from small clinical trials should no longer be conducted,
since these data might not correlate to the expected
efficacy and safety of the vaccine [31]. These arguments
highlight the need to critically evaluate and summarize
the available evidence by focusing on clinical outcomesrather than using surrogate markers of vaccine effective-
ness. However, our review also shows the challenges that
are related with the conduct of observational studies on
influenza VE and when making decisions on regulatory
aspects or vaccine recommendations based on only low or
very low quality of evidence.
In our study, pooled VE estimates against all-cause
mortality and hospitalization due to pneumonia and
influenza were derived from four studies. If they were free
of bias and confounding, they would indicate protective,
albeit small to moderate effects in patients with ESRD.
Given the high rates of respective events in this at-risk
group, even a low effectiveness of 32% and 14% against
all-cause mortality and hospitalization due to influenza or
pneumonia, respectively, would correspond to a NNV of
15 and 42, respectively. Although differences between
ESRD subpopulations are likely as, for example, shown
in one study [24] by statistical significant differences in
baseline characteristics between patients on hemodialysis
and those on peritoneal dialysis, removal of patients on
peritoneal dialysis or with newly diagnosed ESRD from
the meta-analysis did not affect point estimates signifi-
cantly. This was due to the large power of the study by
McGrath et al. [26], which mainly influenced the results.
Therefore, further conclusions from this sensitivity ana-
lysis have to be taken with caution.
When interpreting the VE results on clinical outcomes
reported here, several issues have to be taken into account.
First, risk of bias was high in four studies and unclear in
the remaining one. This was due to inappropriate adjust-
ment for confounders, unclear baseline imbalances of
vaccinated and unvaccinated subpopulations, or strong
indicators of residual confounding such as significant or
even stronger protective vaccine effects outside influenza
seasons. Second, since unspecific outcomes tend to ‘dilute’
the effectiveness of (influenza) vaccines [32], it remains
unclear why VE was found to be higher for all-cause
mortality than for the more specific outcome influenza/
pneumonia hospitalization.
Table 3 Pooled crude and adjusted odd ratios (OR) for influenza-related outcomes during influenza-season and
off-season in vaccinated vs. non-vaccinated end-stage renal disease participants










Bond et al.1 [25] 0.79 (0.72–0.87) 0.73 (0.67–0.81)2 0.90 (0.77–1.10)2 Unclear
Gilbertson3 [24] – 0.77 (0.65–0.90)4 High
McGrath [26] 0.77 (0.76–0.78)5 0.71 (0.70–0.72)5 0.45 (0.41–0.50)6 High
Wang [23] 0.88 (0.73–1.07)7 0.49 (0.41–0.59)7 – High
Pooled estimate 0.77 (0.75–0.80), I2 = 10% 0.68 (0.61–0.76), I2 = 83% – –
Cardiac death#
Gilbertson3 [24] – 0.84 (0.71–0.98)4 – High
Infectious death§
Gilbertson3 [24] – 0.83 (0.65–1.05)4 – High
Hospitalization
All-cause hospitalization
Gilbertson3 [24] – 0.95 (0.85–1.07)4 High
Wang [23] 1.11 (0.96–1.28)7 0.80 (0.69–0.94)7 – High
Pooled estimate – 0.88 (0.74–1.04), I2 = 70% – –
Hospitalization due to
influenza or pneumonia
Gilbertson3 [24] – 0.90 (0.70–1.16)4 High
McGrath [26] 0.90 (0.87–0.92)5 0.84 (0.82–0.84)5 0.74 (0.64–0.85)6 High
Slinin [27] – 0.93 (0.86–1.01) – High
Wang [23] 1.30 (1.08–1.56)7 0.77 (0.64–0.93)7 – High




Gilbertson3 [24] – 0.73 (0.32–1.68)4 – High
Hospitalization due to
respiratory infection
Gilbertson3 [24] – 0.87 (0.69–1.09)4 – High
ICU admission
Wang [23] 0.38 (0.27–0.53)7 0.19 (0.14–0.27)7 – High
Other outcomes
Influenza-like illness
McGrath [26] 0.93 (0.91–0.95)5 0.88 (0.86–0.90)5 0.77 (0.68–0.88)6 High
OR, odds ratio; ICU, intensive care unit.
#Cardiac death, defined according to cause of death reported on the ESRD death notification form (myocardial infarction, pericarditis, atherosclerotic heart
disease, cardiomyopathy, cardiac arrhythmia, cardiac arrest, valvular heart disease, pulmonary edema).
#Infectious death, defined according to cause of death reported on the ESRD death notification form (septicemia, pulmonary infection, viral infection, tuberculosis,
hepatitis B, other viral hepatitis, fungal peritonitis, other infections).
1OR were also reported for those who additionally received pneumococcal vaccine; however, for the purpose of this study these patients were not considered.
2Off-season estimates in months June–August.
3Only patients on peritoneal dialysis.
4Point estimates of two influenza seasons were pooled first.
5Point estimates of four seasons were pooled first.
6Point estimates of four pre-influenza-seasons (defined as 10% of isolates positive for influenza) were pooled first.
7Crude/Adjusted incidence rate ratios.
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Figure 2 Forest plots of observational studies presenting data on vaccine effectiveness in patients with end-stage renal disease.
(A) Adjusted effectiveness of influenza vaccination against all-cause mortality, influenza season; (B) Adjusted effectiveness of influenza vaccination
against all-cause mortality, off-season; (C) Adjusted effectiveness of influenza vaccination hospitalization due to influenza or pneumonia, influenza
season; (D) Adjusted effectiveness of influenza vaccination hospitalization due to influenza or pneumonia, off-season.
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Table 4 GRADE evidence profile for effectiveness of influenza vaccination in patients with end-stage renal disease

























66 fewer per 1,000





10% 32 fewer per 1,000
(from 24 fewer to
39 fewer)
40% 128 fewer per 1,000











None – 5% RR 0.84
(0.71–0.98)5
8 fewer per 1,000





10% 16 fewer per 1,000
(from 2 fewer to
29 fewer)
20% 32 fewer per 1,000











None – 5% RR 0.83
(0.65–1.05)5
9 fewer per 1,000





10% 17 fewer per 1,000
(from 35 fewer to
5 more)
20% 34 fewer per 1,000















107 fewer per 1,000





20% 24 fewer per 1,000
(from 52 fewer to
8 more)
40% 48 fewer per 1,000






























24 fewer per 1,000





5% 7 fewer per 1,000
(from 3 fewer to
10 fewer)
30% 42 fewer per 1,000













None – 5% RR 0.73
(0.32–1.68)5
13 fewer per 1,000





10% 27 fewer per 1,000
(from 68 fewer to
68 more)
20% 54 fewer per 1,000












None – 5% RR 0.87
(0.69–1.09)5
6 fewer per 1,000





10% 13 fewer per 1,000
(from 31 fewer to
9 more)
20% 26 fewer per 1,000





























55 fewer per 1,000





12% 97 fewer per 1,000
(from 88 fewer to
103 fewer)
25% 203 fewer per 1,000











None – 5% RR 0.88
(0.86–0.9)11
6 fewer per 1,000





10% 12 fewer per 1,000
(from 10 fewer to
14 fewer)
20% 24 fewer per 1,000
(from 20 fewer to
28 fewer)
1High risk of bias in two of four studies due to inappropriate adjustment for confounders and unclear baseline imbalance.
2Control group rates available in only two of four studies.
3RR adjusted in all four studies at least for age, sex, and comorbidities.
4High risk of bias due to missing information on comorbidities in vaccinated vs. non-vaccinated participants.
5Adjusted for age, sex, ethnicity, network, length of time with ESRD, cause of renal failure, comorbidity index, and hospital days.
6Control group rate available only for one of two studies.
7RR adjusted in both studies at least for age, sex, and comorbidities.
8High risk of bias in three of four studies due to inappropriate adjustment for confounders, unclear baseline imbalance, and inappropriate follow-up time.
9High risk of bias due to inappropriate adjustment for confounders.
10Significant estimate of effectiveness outside influenza season indicates residual confounding.
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approach used by McGrath et al. [26] when comparing
VE in a year when the vaccine strains did not match
with the circulating strain (unmatched season) with VE
during a well-matched year. This approach can be used
as an additional or alternative strategy to the “pseudo-
effectiveness approach outside seasons” to assess the
risk of bias in observational studies on influenza VE.
Using the unmatched season as ‘working placebo’ did
not reveal a protective effect of influenza vaccination
against any clinical outcome. The authors concluded
that the potential benefit of the influenza vaccine in
patients with ESRD is small to negligible and protective
effects measured using the conventional approach are
likely to be biased. This issue might be driven by the
‘healthy vaccine effect’ and has been discussed previously
for influenza vaccines [33]. It has been suggested that
estimating off-season estimates in observational studies
could be helpful to assess the extent of unmeasured
confounding [34]. However, a recently conducted study
found that even adjusting for more than 100 variables
did not eliminate unmeasured confounding and that,
instead, using the instrumental variable analysis method is
effective in producing less-biased estimates [35]. Further-
more, outcome misclassification could be prevented by
using laboratory-confirmed influenza as an outcome, rather
than unspecific indicators of mortality and morbidity.
Remarkably, we did not identify studies that compared
safety outcomes between vaccinated and unvaccinated
patients with ESRD. In healthy adults, vaccination against
seasonal influenza is not associated with an increased risk
of serious adverse events [36,37]. However, in patients
with ESRD, studies comparing reactogenicity of two differ-
ent influenza vaccines [38] (subunit vs. virosomal) or
assessing the immunogenicity among vaccinated partic-
ipants [39,40] did not show any serious adverse events.
In addition, two studies did not find differences in
adverse event rates after influenza vaccination between
patients with ESRD compared with healthy adults
[41,42]. Although limited by the lack of control groups
and sample size, there is no clear evidence of an increased
risk of severe adverse events following influenza vaccin-
ation in patients with ESRD.
Our study has several strengths. It is the first systematic
review on this topic, covering all data published so far. In
addition, by searching the largest respective data base
(ClinicalTrials.gov) we also aimed at identifying unpub-
lished studies. We performed an outcome-specific quality
assessment of individual studies and considered the qual-
ity of the body of evidence for each outcome by using
GRADE. The limitations of our systematic review were
mainly due to the limitations of the included studies.
Surprisingly, we identified studies from two countries only,
although the number of patients with ESRD requiringdialysis is increasing worldwide [1-3]. Four of five included
studies were conducted in the US, using the same data
source. The USRDS database comprises the largest
population of dialysis patients worldwide; however, the
composition of this population might differ substantially
from ESRD patients from other countries. Moreover, the
USRDS is based on administrative claims data and some
important variables, including the vaccination exposure
might have not been adequately captured. For example,
three studies [24-26] assessed the potential of exposure
misclassification: Bond et al. [25] reported that, in a sub-
sample, vaccination was reported by patients themselves
and was not validated through clinical records. However,
the authors argued that the mortality rate was higher
among patients with self-reported (compared to database-
documented) vaccination status and that therefore incor-
rect self-reports of having received vaccination would have
biased the results towards the null. Gilbertson et al. [24]
concluded that the low vaccination rate observed in their
study might reflect a low sensitivity of the billing data that
was used to determine vaccination status but that inter-
pretation here is difficult. McGrath et al. [26] assumed
that the number of vaccinations missed (e.g., if patients
received a vaccine that was paid out of pocket) would be
low given the fact that the vaccine is paid by the health
maintenance organization covering the study population.
In addition, at least partial overlap of the study population
of the four different US studies cannot be ruled out,
although the studies analyzed different seasons and the
outcomes should be mutually exclusive for each season.
However, multiple inclusions of the same patients could
have artificially equalized point estimates from different
studies. Finally, since our study sample was too small to
formally test for publication bias, this form of bias cannot
be ruled out.
Conclusions
In conclusion, our systematic review indicates that evi-
dence on the protective effects of influenza vaccination
in patients with ESRD is limited and of very low quality.
Evidence on vaccine safety is absent. Therefore, studies
using randomization or quasi-experimental designs are
needed to determine the extent by which vaccination
prevents influenza and related clinical outcomes in this
important risk group. In addition, whether other vaccine
types, such as adjuvant vaccines or high-dose vaccines,
could have larger effects in this population compared to
trivalent inactivated vaccines should also be assessed. Given
the high rates of health-endangering events in these
patients, even a low VE can be considered as sufficient to
recommend annual influenza vaccination. However, physi-
cians should consider influenza in their differential diagno-
sis if ESRD patients present with influenza-like illness
symptoms regardless of whether they are vaccinated or not.
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